{"filing":{"accession_number":"0001193125-26-333817","cik":"0000884624","ticker":"OFIX","company_name":"Orthofix Medical Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"ofix-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/884624/000119312526333817/ofix-20260805.htm"},"events":[{"id":24475,"run_id":22178,"accession_number":"0001193125-26-333817","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"Orthofix Medical Inc. issued a press release on August 5, 2026, announcing second quarter 2026 financial results with net sales of $210.9 million (4% reported, 5% pro forma constant currency growth), a reported net loss of $(15.8) million, and adjusted EBITDA of $20.1 million. The company raised full-year 2026 guidance for both net sales ($845–$855 million) and adjusted EBITDA ($95–$98 million).","company_name":"Orthofix Medical Inc.","ticker":"OFIX","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25036,"accession_number":"0001193125-26-333817","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Orthofix Medical Inc. issued a press release on August 5, 2026, announcing its financial results for the second quarter ended June 30, 2026. The disclosure includes net sales of $210.9 million, reported net loss of $(15.8) million, adjusted EBITDA of $20.1 million, and raised full-year 2026 guidance for both net sales and adjusted EBITDA. This is a standard quarterly earnings release with detailed financial statements and forward-looking guidance, typical of Item 2.02 disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:38:53.186878+00:00","company_name":"","ticker":null,"filing_date":""},{"id":25037,"accession_number":"0001193125-26-333817","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure references a corporate investor relations presentation (Exhibit 99.2) to be used for investor communications, but the substantive content furnished is a news release (Exhibit 99.1) reporting Orthofix's second quarter 2026 financial results. The release discloses Q2 2026 net sales of $210.9 million (4% reported, 5% pro forma constant currency growth), reported net loss of $(15.8) million, adjusted EBITDA of $20.1 million, and raised full-year 2026 guidance for both net sales ($845–$855 million) and adjusted EBITDA ($95–$98 million). This is a material earnings disclosure affecting investor assessment of the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:38:53.186878+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25036,"accession_number":"0001193125-26-333817","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Orthofix Medical Inc. issued a press release on August 5, 2026, announcing its financial results for the second quarter ended June 30, 2026. The disclosure includes net sales of $210.9 million, reported net loss of $(15.8) million, adjusted EBITDA of $20.1 million, and raised full-year 2026 guidance for both net sales and adjusted EBITDA. This is a standard quarterly earnings release with detailed financial statements and forward-looking guidance, typical of Item 2.02 disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:38:53.186878+00:00","company_name":"Orthofix Medical Inc.","ticker":"OFIX","filing_date":"2026-08-05"},{"id":25037,"accession_number":"0001193125-26-333817","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure references a corporate investor relations presentation (Exhibit 99.2) to be used for investor communications, but the substantive content furnished is a news release (Exhibit 99.1) reporting Orthofix's second quarter 2026 financial results. The release discloses Q2 2026 net sales of $210.9 million (4% reported, 5% pro forma constant currency growth), reported net loss of $(15.8) million, adjusted EBITDA of $20.1 million, and raised full-year 2026 guidance for both net sales ($845–$855 million) and adjusted EBITDA ($95–$98 million). This is a material earnings disclosure affecting investor assessment of the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:38:53.186878+00:00","company_name":"Orthofix Medical Inc.","ticker":"OFIX","filing_date":"2026-08-05"}]}